CompletedPhase 2NCT00274807

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Cleveland Clinic
Principal Investigator
Matt E. Kalaycio, MD
The Cleveland Clinic
Intervention
filgrastim(biological)
Enrollment
40 enrolled
Eligibility
16 years · All sexes
Timeline
20012008

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00274807 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials